Targeted Delivery of Therapies

OTCQB: ACXA

Company Presentation – January 2017

Statements made in this presentation that are not historical facts are forward-looking

statements that involve risks and uncertainties. The inclusion of forward-looking statements,

including those related to the ability of the Company to perform per its license agreements

with UCSF and Accelerating Combination Therapies LLC and meet its obligations; the ability

of the Company to successfully develop and commercialize its BranchPoint device and ACX-

31 program, and execute its business plan; the business strategy, plans, and objectives of

the Company; and any other statements of non-historical information should not be regarded

as a representation that any of our plans will be achieved. Actual results may differ materially

from those described in this presentation due to the risks and uncertainties inherent in our

business, including, without limitation, risks and uncertainties related to: our research and

development efforts, including pre-clinical and clinical testing; regulation by the FDA and

other government agencies; the timing of regulatory applications and product launches; our

ability to successfully commercialize our products; and other risks detailed in our filings with

the Securities and Exchange Commission filings, including our most recent Annual Report on

Form 10-K and our most recent Quarterly Report on Form 10-Q.

You are cautioned not to place undue reliance on these forward-looking statements, which

speak only as of the date hereof. We undertake no obligation to revise or update this

presentation to reflect events or circumstances that occur after the date of this presentation.

Forward-Looking Statements

2

• Accurexa is a development-stage biotechnology company focused on the targeted delivery of therapies

• Diversified development pipeline:

� ACX-31 local chemotherapy wafer developed for the treatment of brain cancer in collaboration with Johns Hopkins University

� Combination of ACX-31 wafer with a PARP inhibitor in development (AstraZeneca’s and Clovis Oncology’s PARP inhibitors approved)

� Collaboration with DelMar Pharmaceuticals to develop ACX-31 wafer in combination with DelMar’s VAL-083 small molecule chemotherapeutic

UCSF: University of California, San Francisco(1) Glial Derived Neurotrophic Factor

Investment Highlights

3

� Collaboration with UCSF to deliver stem cell-derived GDNF(1) for treatment of Parkinson’s Disease using Accurexa’s BranchPoint delivery device

• Virtual product development team with integrated Bioengineering, Formulation, Manufacturing, Quality Control, Regulatory capabilities

Pipeline – Targeted Delivery of Therapies

4

ACX-31

Pre-Clinical Clinical

Pre-IND Meeting

Phase 1 Phase 2 Phase 3

ACX-31 + Val-083 Combination

BranchPointParkinson’s Stem Cell Treatment

Pre-IND Meeting

ACX-31 + PARPiCombination

ACX -31implantable local chemotherapy

wafer to treat brain tumors

5

• Glioblastoma Multiforme (GBM) is one of the most aggressive brain cancer types

� ~ 22,000 patients are newly diagnosed with GBM and 15,000 deaths each year in the US

• Accurexa licensed patent for local delivery of temozolomide and BCNU from Dr. Brem(inventor of Gliadel®) at Johns Hopkins University

• Both oral temozolomide and local BCNU are FDA approved for the treatment of GBM

• Oral temozolomide generated US sales of $420 million and global sales of $910 million under its brand name Temodar® in 2012, before it became generic

6

ACX-31 Local Chemotherapy Wafer

Source: Evaluate Ltd., Transparency Market Research, National Cancer Institute

First-line treatment: Temozolomide

• Marketed as Temodar by Merck

• US sales of $420 million and global sales of $910 million before generic entry in 2012

• FDA approved based on improvement of survival by 2.5 months

Gliadel (local BCNU implants)

• Implantable chemotherapy wafers

• Global sales of ~$30-40m

• FDA approved based on improvement of survival by 2.3 months

Avastin

• Marketed by Roche

• Global sales of ~$120 million

• FDA approved based on an improvement in progression free survival but Avastin did not improve overall survival in later studies

Current Standard of Care for Glioblastoma

7

Local delivery covered by

ACX-31 Patent

ACX-31 Potential Market Opportunity

8

Glioblastoma Treatment Global Sales ($ million)

historic and projected

Source: Evaluate Ltd., Transparency Market Research

ACX-31 Potential Market Opportunity

0

200

400

600

800

1000

1200

1400

2012 2013 2014 2015 2016 2017 2018 2019 2020

Potential Market Opportunity created by generic sales erosion of Temodar

Temodar

AvastinGliadel

Current Standard of Care Improves Survival by Months

9Source: UpToDate; Gil-Salu, J., Neurocirugia, 2004; Walker, M., J. Neurosurgery, 1978; Westphal, M., Neuro-Oncology, 2003; Stupp, R., NEJM, 2005; Athanassiou, H., JCO, 2005; Stewart, L., Lancet, 2002; Lai, A., JCO, 2011.

Median Survival (Months) by Therapy

0

2

4

6

8

10

12

14

16

18

Radiation Therapy (RT) RT + Oral Temozolomide RT + Local BCNU

Cost per treatment

Unmet Needs:

• Survival limited by delivery of effective chemotherapy dose to tumor site

• Oral temozolomidelimited by blood-brain-barrier

~$30-40,000(branded pricing)

~$30,000

ACX-31 Could Improve Survival Significantly

10

Median Survival (Days)

• ACX-31’s local delivery of chemotherapy significantly improved survival by 45-90% in comparison to oral delivery in a rat study at Johns Hopkins University

• ACX-31 gradually releases chemotherapy over 4 weeks

0

5

10

15

20

25

30

35

40

45

Control Oral TMZ Local TMZ Local TMZ +

BCNUTMZ: Temozolomide

P=0.001 over oral

P<0.0001 over oral

Advantages of ACX-31’s local

delivery of chemotherapy

• Direct delivery of drug to tumor site

• Achieve effective drug concentration

• Limit systemic side effects

• Reduced frequency of dosage

ACX-31 Development Pathway Confirmed with FDA

11

FDA pre-IND Meeting:

• 505(b)(2) pathway confirmed with one Phase 2 trial followed by one Phase 3 trial

• Non-clinical studies adequate except for one 2-week GLP toxicology large animal study

• Phase 2 to be conducted in patients with recurrent glioblastoma

ACX -31

in combination with PARP inhibitor

12

• PARP (Poly ADP Ribose Polymerase) is a family of proteins that can repair the DNA damage to cancer cells caused by the chemotherapy drug temozolomide

� Inhibiting PARP can potentially increase the effectiveness of temozolomide in damaging cancer cells

• Olaparib is the first PARP inhibitor approved in December 2014 and marketed by AstraZeneca under its brand name Lynparza

� Lynparza generated $156 million in sales in the first nine months of 2016 and AstraZeneca expects $2 billion in peak sales

• Evidence from scientific studies of the synergistic effects of temozolomide in combination with PARP inhibitors in the treatment of cancer

� Phase 1 OPARATIC clinical trial treating brain cancer patients with olaparib and oral temozolomide (Cancer Research UK)

� Phase 1 clinical trials testing olaparib and oral temzolomide in lung cancer and Ewing’s sarcoma (Massachusetts General Hospital)

13

ACX-31 Local Chemotherapy Wafer

PARP inhibitors approved or in Phase 3 development

14

Clinical

Phase 1 Phase 2 Phase 3

FDA Approval

talazoparib

veliparib

niraparib

ACX -31DelMar Collaboration

15

• Development of ACX-31 wafer for the local delivery of DelMar’s VAL-083 in combination with temozolomide and/or BCNU to treat brain cancer and other solid tumors

• Combination will hit two distinct cytotoxic DNA alkylation targets: O6 and N7 of guanine while minimizing systemic toxicity

• Potential synergy against cancer stem cells already established

• DelMar granted exclusive option to license or acquire products for further development and commecialization

• Potential 505(b)(2) pathway based on existing VAL-083 data and DelMar’s Phase I/II clinical trial of VAL-083 in brain cancer patients

ACX-31 DelMar Collaboration

16

VAL-083 + Temozolomide:Potential Activity against Cancer Stem Cells

17BTIC: Brain Tumor Initiating Cells

A Novel Combination Therapy for Brain Cancer

18

• Leverages Accurexa’s experience with temozolomide + BCNU combination product

� Accurexa had successful pre-IND Meeting with FDA

� Prof. Brem (inventor of GliadelTM) at Johns Hopkins University serves as advisor

• Leverages DelMar’s research regarding VAL-083 mechanism of action

� Activity against MGMT(+) glioblastoma and brain tumor initiating stem cells

� DelMar had successful VAL-083 Phase I/II clinical trial and End-of-Phase II meeting with FDA

BranchPointlocal delivery of brain therapeutics

19

Straight needle — Current standard of care

20

• Delivery with regular syringes with straight needle requires multiple straight penetrations

• Some patients receive up to 16 separate brain penetrations in stem cell trials

Multiple cranial penetration with risks bleeding or stroke

BranchPoint’s curved, flexible catheter delivers therapeutics to multiple target areas with single penetration

Silvestrini, et al, Mol Therapy, 2014 21

BranchPoint delivers therapeutics without reflux or leakages

No reflux or leakage found on using BranchPoint for brain therapeutics

delivery

22

Reflux of at least 75% is observed when the straight, rigid syringe is

used for delivery of brain therapeutics

Source: Silvestrini MT, Yin D, Coppes VG, Mann P, Martin AJ, Larson PS, Starr PA, Gupta N, Panter SS, Desai TA, Lim DA. Radially branched deployment for more efficient cell transplantation at the scale of the human brain. Stereotact Funct Neurosurg. 2013;91(2):92-103.

• BranchPoint allows local delivery of multiple therapeutics, e.g. stem cells, chemotherapy, gene therapy

� Funded with $1.8 million by California’s Stem Cell Agency CIRM

• UCSF Collaboration

� CNS10-NPC are human neural stem cells that express Glial-Derived Neurotrophic Factor (GDNF) for the treatment of Parkinson's Disease

� CNS10-NPC to be delivered by BranchPoint device

BranchPoint Parkinson’s Stem Cell Treatment

23UCSF: University of California, San Francisco

Parkinson’s caused by lack of neurotransmitter dopamine

Team Accurexa – Lean, virtual organization leverages capabilities of collaboration partners

24

George Yu, MDPresident & CEO

Greg MathisonRegulatory & Quality

Assurance

William CallahanBoard Director

Agnes CobbumRegulatory Affairs

Avi DombFormulation,

Manufacturing

Clinical and Scientific Advisors

25

• Dr. Henry Brem, Professor of Neurosurgery and Director of

Neurosurgery Department, Johns Hopkins University – Built one of the

largest brain tumor research and treatment centers in the world. Invented and

developed Gliadel® wafers to locally deliver chemotherapy to brain tumors.

• Dr. Betty Tyler, Associate Professor of Neurosurgery, Johns Hopkins

University – Runs a highly successful laboratory in the field of translational

research. Assisted in preclinical studies that led to bringing Gliadel® to brain

tumor patients as standard of care.

• Dr. Daniel Lim, Associate Professor of Neurological Surgery, UCSF –

Lead inventor of BranchPoint with over 18 years of research experience in

neural stem cell therapies and brain tumors. Co-surgeon in Stem Cells Inc.’s

Phase 1 clinical trial of neural cell transplantation to PMD patients.

Financial Summary

26

• OTCQB Ticker: ACXA

• Common Shares Outstanding: 9,198,954 (as of 11/4/2016)

• Cash: $1,458,126 (as of 9/30/2016)

• $2.25m Equity Financing from Sabby Capital in June 2015